Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Patent
1993-06-07
1995-04-11
Fan, Jane T.
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
548520, 546270, 546256, C07D20976
Patent
active
054059666
ABSTRACT:
Conjugates of trichothecenes and agents that bind to a defined population of cells are disclosed. Preferred are conjugates of trichothecene molecules with polyclonal or monoclonal antibodies or fragments thereof that recognize antigens that are present only on tumor cells or are augmented in their expression on tumor cells as compared to normal tissues. Trichothecene molecules are coupled to the agent through non-covalent and covalent linkages, such as peptide bonds, disulfide bonds, thioester bonds, or thioether bonds. A method for inhibiting the growth and metabolism of antigen-positive cells is also disclosed. Derivatized trichothecene compounds prepared for conjugation to targeting agents are also disclosed.
REFERENCES:
patent: 4507234 (1985-03-01), Kato et al.
patent: 4618585 (1986-10-01), Chan
patent: 4624846 (1986-11-01), Goldenberg
F. S. Chu et al., Appl. Environ. Microbiol., 1984, 48 (4), pp. 781-784 "Production and Characterization of Antibody Against Deoxyverrucarol".
K. W. Hunter, Jr. et al., Chem. Abstr. 102:76957n (1985), "Preparation and characterization of monoclonal antibodies to the trichothecene mycotoxin T-2".
J. R. Bamburg, Prog. Molec. Subcell. Biol. 8:41-110 (1983), "Biological and Biochemical Actions of Trichothecene Mycotoxins".
J. W. Uhr, J. Immunol. 133:i-x (1984), "Immunotoxins: Harnessing Nature's Poisons".
B. M. J. Foxwell, Immunotoxicology, Academic Press, London, (1983) pp. 359-368 "Monoclonal antibody-toxin conjugates as selective cytotoxic agents".
Protection Against Trichothecene Mycotoxins, National Academy Press, Washington, D.C., (1983), pp. 17-20; 129-136, "The Trichothecene Mycotoxins: Their Structure, Natural Production, and Levels of Occurrence".
Murphy et al., Cancer Treatment Rep., 62, (1978), pp. 1497-1502, "Phase I Clinical Evaluation of Anguidine".
Adler et al., Cancer Treatment Rep., 68 (1984), pp. 423-425, "Anguidine: A Broad Phase II Study of the Southeastern Cancer Study Group".
Heikkila et al., J. Biol. Chem., vol. 262, 34, Dec. 5, 1987, pp. 16456-16460, "Bomesin-related peptides induce calcium mobilization in a subset of human small cell lung cancer cell lines".
Kris et al., J. Biol. Chem., vol. 262, 23, Aug. 15, 1987, pp. 11215-11220, "Identification of the bombesin receptor on murine and human cells by cross-linking experiments".
Carney et al., Cancer Research, 47, Feb. 1, 1987, pp. 821-825, "Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide".
Sausville et al., J. Biol. Chem., vol. 261, 5, Feb. 15, 1986, pp. 2451-2457, "Expression of the gastrin-releasing peptide gene in human small cell lung cancer".
Gargosky et al., Biochem J. (1987) vol. 247, pp. 427-432 (printed in Great Britain), "C-Terminal bombesin sequence requirements for binding and effects on protein synthesis in Swiss 3T3 cells".
A. Huntley Blair and Tarun I. Ghose, J. Immunol. Meth. (1983) vol. 59, pp. 129-143, "Linkage of cytotoxic agents to immunoglobulins".
Carlsson, J. et al., "Protein Thiolation and Reversible Protein-Protein Conjugation, N-Succinimidyl 3-(2-Pyridyldithio)Propionate, A New Heterobifunctional Reagent", Biochem J., vol. 173, pp. 723-737, 1978.
Anderson, D. W. et al., "Structure-Activity Studies of Trichothecenes: Cytotoxicity of Analogues and Reaction Products Derived from T-2 Toxin and Neosolaniol", J. Med. Chem., vol. 32, pp. 555-562, 1989.
Kaneko, T. et al., "Structural Modifications of Anguidin and Antitumor Activities of its Analogues", J. Med. Chem., vol. 25, pp. 579-589, 1982.
Geoghegan, K. F. et al., "Site-Directed Conjugation of Nonpeptide Groups to Peptides and Proteins via Periodate Oxidation of 2-Amino Alcohol. Application to Modification at N-Terminal Serine", Bioconjugate Chem., vol. 3, pp. 138-146, 1992.
Braslawsky, G. R. et al., "Antitumor Activity of Adriamycin (Hydrozone-linked) Immunoconjugates compared with Free Adriamycin and Specificity of Tumor Cell Killing", Cancer Research, vol. 50, pp. 6608-6614, 1990.
Jarvis, B. B. et al., "Antileukemic Compounds Derived by Chemical Modification of Macrocyclic Trichothecenes. 2. Derivatives of Roridins A and H and Verrucarins A and J", J. Med. Chem., vol. 27, pp. 239-244, 1984.
Jarvis, B. B. and Mazzola, E. P., "Macrocyclic and Other Novel Trichothecenes: Their Structure, Synthesis, and Biological Significance", Acc. Chem. Res., vol. 15, pp. 388-395, 1982.
Tricothecene Mycotoxicosis: Pathophysiologic Effects, vol. I, V. R. Beasley (ed.), CRC Press, Boca Raton, Fla., 1989, Chapter 5, pp. 73-105, Jarvis, B. B. and Acierio, A. M., "Anticancer Properties of Trichothecens".
Medicinal Chemistry, Cassidy, J. M. and Douros, J., vol. 16, Chapter 2, pp. 43-72, New York, Academic Press, 1980, Doyle, T. W. and Bradner, W. T., "Trichothecanes".
Abrams Paul G.
Kasina Sudhakar
Reno John M.
Sanderson James A.
Theodore Louis J.
LandOfFree
Trichothecene conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Trichothecene conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Trichothecene conjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1539484